Ultragenyx Pharmaceutical (MEX:RARE) Other Current Liabilities: MXN2,705 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:RARE Ultragenyx Pharmaceutical Inc MEX:RARE
70 GF Score
Price MXN1,150.56
GF Value MXN1,699.44
! 5 Warning Signs
View Full Analysis

What is Ultragenyx Pharmaceutical Other Current Liabilities?

Ultragenyx Pharmaceutical MEX:RARE 70 Other Current Liabilities is MXN2,705 Mil as of Mar. 2026. GuruFocus rates MEX:RARE with a GF Score™ of 70/100 and a GF Value™ of MXN1,699.44. The stock has 5 warning signs investors should review.

Ultragenyx Pharmaceutical's other current liabilities for the quarter that ended in Mar. 2026 was MXN2,705 Mil.

Ultragenyx Pharmaceutical's quarterly other current liabilities increased from Sep. 2025 (MXN2,239 Mil) to Dec. 2025 (MXN2,395 Mil) and increased from Dec. 2025 (MXN2,395 Mil) to Mar. 2026 (MXN2,705 Mil).

Ultragenyx Pharmaceutical's annual other current liabilities increased from Dec. 2023 (MXN785 Mil) to Dec. 2024 (MXN1,814 Mil) and increased from Dec. 2024 (MXN1,814 Mil) to Dec. 2025 (MXN2,395 Mil).

Ultragenyx Pharmaceutical Other Current Liabilities Related Terms

Ultragenyx Pharmaceutical Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Ultragenyx Pharmaceutical's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ultragenyx Pharmaceutical Other Current Liabilities Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 785.42 1,814.45 2,394.76

Ultragenyx Pharmaceutical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,054.92 2,154.48 2,239.06 2,394.76 2,704.91
MEX:RARE
70GF Score
Ultragenyx Pharmaceutical Inc MEX:RARE
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ultragenyx Pharmaceutical Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of MXN2,705 Mil mean?
Ultragenyx Pharmaceutical (MEX:RARE) has a Other Current Liabilities of MXN2,705 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ultragenyx Pharmaceutical.
Is Ultragenyx Pharmaceutical's Other Current Liabilities too high?
Ultragenyx Pharmaceutical's current Other Current Liabilities is MXN2,705 Mil. Overall, Ultragenyx Pharmaceutical has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Ultragenyx Pharmaceutical's Other Current Liabilities compare to VERA and IRON?
Ultragenyx Pharmaceutical's Other Current Liabilities of MXN2,705 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical's current Other Current Liabilities is MXN2,705 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ultragenyx Pharmaceutical stock overvalued right now?
Ultragenyx Pharmaceutical (MEX:RARE) has a current Other Current Liabilities of MXN2,705 Mil. The stock's GF Value™ is MXN1,699.44, compared to a current price of MXN1,150.56 — trading 32.3% below its estimated fair value. The current Other Current Liabilities is MXN2,705 Mil. Ultragenyx Pharmaceutical's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Ultragenyx Pharmaceutical (MEX:RARE), the current Other Current Liabilities is MXN2,705 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ultragenyx Pharmaceutical (MEX:RARE) Overvalued in 2026?

Based on GuruFocus' analysis, Ultragenyx Pharmaceutical stock appears to be undervalued. The current stock price of MXN1,150.56 is trading 32.3% below its estimated GF Value™ of MXN1,699.44.

Key valuation signals for MEX:RARE:

  • Other Current Liabilities: MXN2,705 Mil
  • GF Value™: MXN1,699.44 vs. price of MXN1,150.56 (32.3% below fair value)
  • GF Score™: 70/100 with 5 warning signs

No single metric tells the full story. See the MEX:RARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ultragenyx Pharmaceutical Business Description

Address 60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
70GF Score

Get the complete analysis for MEX:RARE

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN1,150.56
Price
MXN1,699.44
GF Value